Abivax
5, rue de la Baume
Paris
75008
France
Tel: 33-0-1-53-83-08-41
Website: http://www.abivax.com/en/
Email: info@abivax.com
169 articles about Abivax
-
Abivax to Present at the 39th Annual J.P. Morgan Healthcare Conference Ahead of Major Clinical Milestones
12/21/2020
Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday,
-
Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies
12/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021
12/9/2020
Pivotal ABX464 clinical trials ongoing or planned for three indications: Ulcerative colitis, Crohns disease and Covid-19 Four phase 1 studies are being initiated to generate complementary data to support the late-stage development program of ABX464 Discussions planned with regulatory agencies in Europe, the US and Japan to seek recommendations and agreement with the phase 3 development approach in ulcerative colitis and Crohns disease
-
Abivax 2021 Financial Communication Calendar
12/3/2020
Abivax (Euronext Paris:FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar. Thursday, April 1, 2021 Publication of financial statements as of December 31, 2020 Friday, April 30, 2021 Publication and release of the 2020 annual financial report Friday, June 4, 2021
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
Abivax Completes Recruitment of ABX464 Phase 2b Induction Study in Ulcerative Colitis
11/30/2020
Recruitment of 232 patients completed ahead of schedule with minimal impact by the Covid-19 pandemic
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Abivax Announces the Success of Its Oversubscribed Capital Increase of EUR 28m at Market Price
10/29/2020
Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
-
BioSpace Global Roundup, Oct. 15
10/15/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Abivax Secures EUR 15m Non-dilutive Financing from Kreos Capital
10/13/2020
EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees
-
Abivax Presents First-Half 2020 Financial Results and Operations Update
9/24/2020
Abivax today announces its 2020 half-year financial results, as of June 30, 2020, and provides an update on its pipeline progress.
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Clinical Catch-Up: June 22-26
6/29/2020
It was a busy week for clinical trial updates. Here’s a look. -
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
6/15/2020
Abivax SA (Euronext Paris:FR0012333284 - ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that it has received € 5m in non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE - Prêts Garantis par l'Etat).
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
BioSpace Global Roundup, March 19
3/19/2020
Companies from across the globe provide updates on their business operations and pipeline development. -
Abivax 2019 Financial Results and Operations Update
3/16/2020
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced its 2019 yearly financial results, as of December 31, 2019, and provided an update on progress in its product pipeline.